(¿Â¶óÀÎ)´ëÇÑÁ¾¾ç³»°úÇÐȸ 4/7 ºÐ±âÁý´ãȸ : 2022-04-07±³À°ÀÏÀÚ : 2022-04-07
±³À°Àå¼Ò : ¿Â¶óÀÎÄÁÆÛ·±½º
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ)´ëÇÑÁ¾¾ç³»°úÇÐȸ 4/7 ºÐ±âÁý´ãȸÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
meetings@ksmo.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-07 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 18:00~18:40 Biliary Tract Cancer and Conversion Surgery °¹öµé(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 04-07 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 18:40~19:20 Pancreatic Cancer and Conversion Surgery ±èÀÏȯ(ÇØ¿î´ë¹éº´¿ø)
±³À°½Ã°£ 04-07 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 19:20~20:00 Immune checkpoint combination as 1st line option in NSCLC ¿ÀÃæ·Ä(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 04-07 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 20:00~21:00 Sequential treatment strategy of NSCLC patients harboring ALK fusion ±èâ°ï(¿¬¼¼¾Ïº´¿ø)